Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

The Three-Substituted Indolinone Cyclin-Dependent Kinase 2 Inhibitor 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) Kills Human Leukemia Cells via Down-Regulation of Mcl-1 through a Transcriptional Mechanism

Ning Gao, Lora Kramer, Mohamed Rahmani, Paul Dent and Steven Grant
Molecular Pharmacology August 2006, 70 (2) 645-655; DOI: https://doi.org/10.1124/mol.106.024505
Ning Gao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lora Kramer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohamed Rahmani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Dent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Grant
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 70 no. 2 645-655
DOI 
https://doi.org/10.1124/mol.106.024505
PubMed 
16672643

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Received March 16, 2006
  • Accepted May 3, 2006
  • Published online July 18, 2006.

Article Versions

  • Earlier version (May 3, 2006 - 12:44).
  • You are viewing the most recent version of this article.
Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Ning Gao,
  2. Lora Kramer,
  3. Mohamed Rahmani,
  4. Paul Dent and
  5. Steven Grant
  1. Departments of Medicine (N.G., L.K., M.R., S.G.), Biochemistry (S.G., P.D.), and Pharmacology, Virginia Commonwealth University and Massey Cancer Center, Richmond, Virginia (S.G.)
  1. Address correspondence to:
    Dr. Steven Grant, Division of Hematology/Oncology, MCV Station Box 230, Virginia Commonwealth University/Medical College of Virginia, Richmond, VA 23298. E-mail: stgrant{at}hsc.vcu.edu
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: May 2006 to September 2023

AbstractFullPdf
May 2006150216
Jun 200680129
Jul 2006201975
Aug 2006173239
Sep 2006223338
Oct 200692317
Nov 2006271018
Dec 2006151215
Jan 2007111710
Feb 2007251911
Mar 2007271125
Apr 200714119
May 200717138
Jun 2007111011
Jul 20071598
Aug 2007121415
Sep 2007101611
Oct 2007112420
Nov 200762418
Dec 200761117
Jan 200814137
Feb 2008171316
Mar 200813159
Apr 200826138
May 2008451917
Jun 2008202114
Jul 2008501411
Aug 2008556811
Sep 200859459
Oct 2008222616
Nov 2008531210
Dec 20085169
Jan 200919115
Feb 2009121411
Mar 2009381717
Apr 2009271513
May 2009121413
Jun 2009978
Jul 200915159
Aug 2009121118
Sep 20091097
Oct 2009361225
Nov 200924914
Dec 20095748
Jan 20108865
Feb 201051117
Mar 20101179
Apr 20101665
May 2010161210
Jun 2010301812
Jul 201023156
Aug 2010321212
Sep 20102594
Oct 2010101115
Nov 20109136
Dec 2010485
Jan 201113204
Feb 20117216
Mar 2011141911
Apr 201111158
May 2011111713
Jun 201181313
Jul 201119117
Aug 2011121217
Sep 201110169
Oct 20118226
Nov 2011321820
Dec 2011161310
Jan 201212159
Feb 20125187
Mar 201227138
Apr 20121187
May 20121385
Jun 20129711
Jul 201228912
Aug 201217814
Sep 2012101417
Oct 201216615
Nov 20121167
Dec 201271611
Jan 2013292610
Feb 20139104
Mar 2013141912
Apr 20131688
May 2013131210
Jun 201317813
Jul 2013663
Aug 2013473
Sep 2013975
Oct 201316154
Nov 2013572
Dec 201310222
Jan 20141284
Feb 20148167
Mar 20149125
Apr 201411104
May 20146144
Jun 20141561
Jul 20141451
Aug 20147119
Sep 2014464
Oct 201416135
Nov 20144166
Dec 20146133
Jan 20152076
Feb 20151049
Mar 201512148
Apr 2015151112
May 2015161710
Jun 201514156
Jul 20151735
Aug 20159154
Sep 2015543
Oct 2015683
Nov 20151248
Dec 2015865
Jan 20161657
Feb 20161157
Mar 201613415
Apr 20167810
May 20161169
Jun 201614413
Jul 2016341422
Aug 2016101917
Sep 2016260
Oct 2016111210
Nov 20167117
Dec 20163712
Jan 201742320
Feb 2017392
Mar 20174188
Apr 201741012
May 20178511
Jun 20176197
Jul 20176154
Aug 20173181
Sep 20174118
Oct 20176185
Nov 20175126
Dec 20173185
Jan 2018691
Feb 201851411
Mar 20186149
Apr 20186247
May 20184164
Jun 20185151
Jul 201851012
Aug 201881914
Sep 20185136
Oct 20188142
Nov 20183182
Dec 20181253
Jan 20192104
Feb 20191732
Mar 20191835
Apr 201919219
May 20192511
Jun 20191512
Jul 20191324
Aug 20192612
Sep 20193002
Oct 20192311
Nov 20192312
Dec 20191132
Jan 20201811
Feb 20201244
Mar 2020733
Apr 2020311
May 20201011
Jun 20202210
Jul 20201133
Aug 2020400
Sep 20201511
Oct 20201713
Nov 2020713
Dec 20203211
Jan 2021812
Feb 2021811
Mar 20212425
Apr 20212610
May 20211023
Jun 20211420
Jul 20211911
Aug 20211035
Sep 2021621
Oct 20212900
Nov 20212011
Dec 20212100
Jan 20222611
Feb 20221020
Mar 20221010
Apr 20222512
May 20222310
Jun 20221732
Jul 20222034
Aug 2022823
Sep 20221310
Oct 20221115
Nov 20221232
Dec 2022710
Jan 20232910
Feb 20232110
Mar 20231510
Apr 20231822
May 2023913
Jun 20231000
Jul 20231832
Aug 20231111
Sep 20231100

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 70 (2)
Molecular Pharmacology
Vol. 70, Issue 2
1 Aug 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Three-Substituted Indolinone Cyclin-Dependent Kinase 2 Inhibitor 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) Kills Human Leukemia Cells via Down-Regulation of Mcl-1 through a Transcriptional Mechanism
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

The Three-Substituted Indolinone Cyclin-Dependent Kinase 2 Inhibitor 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) Kills Human Leukemia Cells via Down-Regulation of Mcl-1 through a Transcriptional Mechanism

Ning Gao, Lora Kramer, Mohamed Rahmani, Paul Dent and Steven Grant
Molecular Pharmacology August 1, 2006, 70 (2) 645-655; DOI: https://doi.org/10.1124/mol.106.024505

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

The Three-Substituted Indolinone Cyclin-Dependent Kinase 2 Inhibitor 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) Kills Human Leukemia Cells via Down-Regulation of Mcl-1 through a Transcriptional Mechanism

Ning Gao, Lora Kramer, Mohamed Rahmani, Paul Dent and Steven Grant
Molecular Pharmacology August 1, 2006, 70 (2) 645-655; DOI: https://doi.org/10.1124/mol.106.024505
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Analgesic Effects and Mechanisms of Licochalcones
  • Induced Fit Ligand Binding to CYP3A4
  • Englerin A Inhibits T-Type Channels
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics